Trial Profile
Assessment of Hand Funtion Pre and Post Anti-tumour Necrosis Factor-a (TNF) Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 26 Feb 2016 Planned number of patients changed from 20 to 13 as reported by United Kingdom Clinical Research Network.
- 25 Feb 2016 Accrual to date is 100% as reported by United Kingdom Clinical Research Network.
- 25 Feb 2016 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.